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Abstract: Background: The hypothalamic–pituitary axis by secreting neuropeptides plays a key role
in metabolic homeostasis. In light of the metabolic regulation, oxytocin is a potential neuropeptide for
therapies against obesity and related disorders. The aim of our study is to measure ghrelin-induced
oxytocin secretion in rats and to detect the changes after administration of ghrelin antagonist.
Methods: Ghrelin was administrated centrally (intracerebroventricular, i.c.v., 1.0, 10.0, and 100.0 pmol)
or systemically (intravenous, i.v., 1.0, and 10.0 nmol). [D-Lys3]-GHRP-6 ghrelin antagonist was
injected 15 min before ghrelin injection in a dose of 10.0 pmol i.c.v. and 10.0 nmol i.v. Results:
Either i.c.v. or i.v. administration of ghrelin dose-dependently increased the plasma oxytocin
concentration. Following pretreatment with the ghrelin antagonist [D-Lys3]-GHRP-6, the high plasma
oxytocin level induced by ghrelin was significantly reduced. Conclusion: The results indicate that the
release of oxytocin is influenced directly by the ghrelin system. Examination of the mechanism of
ghrelin-induced oxytocin secretion is a new horizon for potential therapeutic options.
Keywords: ghrelin; ghrelin antagonist; oxytocin; neuropeptide regulation
1. Introduction
The increasing prevalence of energy metabolism disorders and diseases are both a public health
issue and clinical problem. It has been established that the energy homeostasis plays a role in
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controlling the synthesis and secretion of various hormones, thus any disturbance in these contributes
to the impairment of the metabolic regulation. The central nervous system (CNS), especially the
hypothalamus and pituitary, are important to promote the action of the metabolic regulatory mediators
and influence, e.g., the appetite [1].
Ghrelin is a 28-amino acid-containing endogenous ligand for the growth hormone secretagogue
receptor 1a (GHS-R1a) linking the CNS with peripheral tissues that regulate food intake and energy
homeostasis. The expression of ghrelin has been demonstrated in various tissues, such as the stomach,
kidney, pituitary gland and, hypothalamus [2]. Previous studies suggest that ghrelin could contribute
to metabolic disturbances. Low plasma ghrelin is associated with insulin resistance, hypertension, and
increase the risk of type 2 diabetes [3] and metabolic syndrome [4].
In our previous study, we reported that vasopressin and oxytocin secretion are increased following
the intracerebroventricular (i.c.v.) or intravenous (i.v.) administration of ghrelin in cell cultures of
neurohypophyseal tissue. The results indicate that vasopressin and oxytocin release are influenced
directly by the ghrelin system, and the effects of ghrelin on vasopressin and oxytocin secretion from
the neurohypophyseal tissue in rats can occur at the level of the posterior pituitary [5].
In light of the importance of hypothalamic–pituitary axis and its mediators in metabolic regulation,
oxytocin has a pivotal role in the energy homeostasis. Activation of central and peripheral oxytocin
receptors also regulates energy expenditure [6]. Oxytocin promotes glucose uptake and stimulates
insulin secretion [7]. Zhang et al. found that oxytocin improved the lipid profile by lowering serum
low density lipoprotein and cholesterol levels [8]. Summarizing the results it can be concluded that
hypothalamic–pituitary pathways and its neuropeptides are closely linked to metabolic regulation.
Hence, the examination and identification of the neuroendocrine processes are necessary to understand
the exact effects of neuropeptides, which promote further studies for metabolic changes.
In our previous work we proved that ghrelin administration enhances oxytocin secretion in
neurohypophyseal cell cultures. Based on our in vitro results, the aim of our current study is to
examine the effects of centrally and systemically administrated ghrelin on oxytocin release in rats.
Furthermore, the effect of ghrelin receptor (GHS-R1a) antagonist [D-Lys3]-GHRP-6 has been also
measured on plasma oxytocin secretion.
2. Results
2.1. Effects of Centrally (i.c.v.) and Systemically (i.v.) Administrated Ghrelin on Oxytocin Secretion
Following the i.c.v. administration of 1 pmol ghrelin, the plasma oxytocin level significantly
increased. After administration of a higher ghrelin dose (10 pmol and 100 pmol), the oxytocin secretion
was further enhanced, but no significant difference was observed between the effects of 10 or 100 pmol
doses. Data are presented in Figure 1.
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Figure 1. Dose–response effects of centrally (i.c.v.) administrated ghrelin on plasma oxytocin release 
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Figure 1. Dose–response effects of centrally (i.c.v.) administrated ghrelin on plasma oxytocin release
(expressed as pg/ml). Results shown as eans ± S.E.M., n = 10. Statistical significance: * p < 0.05
relative t control group.
Molecules 2019, 24, 735 3 of 8
As shown in Figure 2, i.v. injections of ghrelin significantly enhanced the plasma oxytocin values.
Both 1 and 10 nmol doses of ghrelin resulted same elevation in oxytocin level.
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Figure 2. Effects of systemically (i.v.) administered ghrelin on oxytocin secretion (expressed as pg/ml).
Results shown as means ± S.E.M., n = 10. Statistical significance: * p < 0.05 relative to the control group.
2.2. Effects of Centrally (i.c.v.) and Systemically (i.v.) Administrated Ghrelin Antagonist on Oxytocin Secretion
The i.c.v. administered ghrelin antagonist [D-Lys3]-GHRP-6 did not induce any significant changes
in oxytocin concentration compared to the control group. However, the higher oxytocin levels induced
by ghrelin were significantly decreased, though the plasma oxytocin concentration remained above
t e control level. Data are presented in Figure 3.
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After the i.v. administration of the ghrelin antagonist, changes in the oxytocin concentration were
not observed. The high plasma oxytocin levels induced by ghrelin were fully blocked, and the control
level was observed. Data are presented in Figure 4.
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2.3. Behavioral Changes at the End of the Experimental Period
Available data suggest that ghrelin possesses a dual role in stress and related behavioral
disorders [9] as well as it can change feeding behavior [10]. During this 30-min-experiment, we did
not observe behavioral changes or a significant change in the consumption of the rats.
3. Discussion
A growing body of evidence indicates that metabolic disorders are significantly linked to the
dysregulation of the CNS. Considering th importance f hypothalamic–pituitary axis i metabolic
regulation, the objective of our current study was to investigate t e basic reg latory pathways t the
site of hypothalamus/pituitary [11]. Numerous studies examine and prove the effects of oxytocin
as a potential therapeutic option [12]. Using an animal model, Camerino reported that t ci or
oxytocin receptor knock ut mice gained weight combined with i paired glucose home stasis [13].
E periments in rodents and preclinical studies show that exogenous oxytocin administration reduces
caloric consumption and produces weight loss [14–16]. W used an alternative way by admi istrating
(i.c.v or i.v.) of ghrelin to increas oxytocin signaling.
As regards the mechanism of ghreli , we presume that ghrelin stimulates oxytocin release by
acting directly on oxytocin-producing neurons in the hypothalamic paraventricular or supr optic
nuclei [17,18]. Previ us data suggest that i.c.v. admi istration of ghrelin increases c-Fos immunoreactivity,
which shows that ghrelin modulates neuronal activity in the hypothalamic paraventricular nucleus [19].
Consequently, there is a functional link between ghrelin a d oxytocin producing cells/ oxytocin
neuropeptide. Olszewski et al. demonstrated that oxytocin serves as a negative feedback regulator
in feedi -related mechanisms driven by ghrelin. Interplay of ghrelin and oxytocin may limit
ghrelin-induced excessive level of food intake, whereas interactions with orexigenic peptides
(e.g., orexin and neuropeptide Y) promote ghrelin-induced food intake [10]. Based on our earlier
bservations related to neurohypohyseal oxytocin secretion, the stimulatory effect betwee oxytocin
and ghrelin seems to e similar by i.c.v. and i.v. administration of ghrelin. The mode of the
oxytocin-increasing action of systemically administered ghrelin has not been fully clarified. Circulating
g relin cannot penetrate the blood–brain barrier and activate the hypothalamic magnocellular cells
since the ghrelin molecule is too large to pass through the blood–brain barrier. It seems that oxytocin
is released directly from t e neurohypophysis. We earlier reported that disperse cell cultures of
neurohypophysis isolated from adult rats are capable of synthesizing and releasing oxytocin [20,21].
Our observatio s on neuro ypophyseal cultures proved the significant role of pituicytes in the
ghrelin-induced changes in oxytocin excretion. To verify that ghrelin influences oxytocin secretion, we
carried out examinations with a specific ghrelin receptor antagonist. The synthetic ghrelin antagonist
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[D-Lys3]-GHRP-6 (His-DTrp-DLys-Trp-DPhe-Lys-NH2) is widely applied under various experimental
conditions [22]. We observed that the higher plasma oxytocin level induced by ghrelin was significantly
decreased by the ghrelin antagonist administered before the ghrelin injection.
It is interesting that ghrelin antagonists could also moderate the neurohypophyseal hormone
release-increasing effect of ghrelin only if the antagonists are administered before ghrelin treatment [5];
if ghrelin administration precedes application of the antagonists, the ghrelin receptor antagonists
prove ineffective: the increase in oxytocin production is not changed at all. In earlier studies [20,21] we
observed the same phenomenon in connection with dopamine or serotonin regulation.
Our present findings prove that the plasma oxytocin level is increased following ghrelin
administration, and that the GHS-R1a ghrelin antagonist can block the enhancement of oxytocin
secretion induced by i.c.v. or i.v. administered ghrelin. Both neurohypophyseal and plasma oxytocin
secretion by ghrelin is a pivotal step in improving the understanding of oxytocin physiology and
potential application. The importance of ghrelin/oxytocin neuropeptides at hypothalamus/pituitary
sites promote new horizon for metabolic disorders. Although the basic mechanism of ghrelin-induced
oxytocin secretion is verified, further studies are necessary to investigate the potential therapeutic
option of oxytocin in special models.
4. Materials and Methods
4.1. Experimental Protocol
The experiments were performed on 3- to 4-month-old male Wistar rats, ranging in weight from
180 to 250 g (bred in our animal house; breeding stock from the Laboratory Animal Insitute, Gödöllo˝,
Hungary). The animal care and research protocols were in accordance with the guidelines of our
university. In our experiment, all efforts were made to minimize the number of animals as well as the
animal suffering.
Ghrelin was administered i.v. into the lateral tail vein or i.c.v. into the right lateral cerebral
ventricle. For i.c.v. administration, the anesthetized rats were cannulated 7 days before the experiment.
The animals were fixed in a stereotaxic instrument, a hole was drilled into the right parietal bone,
and a cannula (Plastics One, Raonake, VA, USA) was inserted into the right lateral ventricle 0.7 mm
anterior and 1.0 mm lateral to the bregma, according to the stereotaxic atlas. The length of the cannula
was 4.0 mm, starting from the cranial bone. The cannula was fixed to the surface of the bone with
rapidly hardening dental cement.
For i.v. administration, the ghrelin dose was 1.0 or 10.0 nmol in 200 µL of saline. For the i.c.v.
injection of ghrelin, the dose was 1.0, 10.0, or 100.0 pmol in 10 µL of saline in 1 min, via a Hamilton
syringe. [D-Lys3]-GHRP-6 was administered i.c.v. in a dose of 10.0 pmol in 10 µL of saline in 1 min,
15 min before ghrelin administration. For i.v. administration of the ghrelin antagonist, the dose was
10.0 nmol in 200 µL of saline in 1 min, 15 min before ghrelin injection. In the control rats, 10 µL of
physiological NaCl solution was administered i.c.v., and 200 µL of NaCl solution was administered i.v.
Thirty min following the administrations of ghrelin or ghrelin antagonist, the rats were decapitated
and the blood was collected in cooled polystyrene tubes. The position of the i.c.v. cannula was checked
by the injection of 1% methylene blue (Reanal, Budapest, Hungary) following coronal section of
the brain. If the position of the cannula was not correct, these cases (6.5%) were excluded from the
assessment of the results. The experimental protocol of the study is presented in Figure 5.
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Figure 5. The experimental protocol of the study. i.c.v. = intracerebroventricular/central administration;
i.v. = intraven us/systemic administration.
4.2. Plasma Oxytocin Determination
The oxytocin levels were measured by the RIA technique [5]. Synthetic oxytocin served as
reference preparation for radiolabelling and specific oxytocin antibody was used (Bachem, CA, USA).
Reverse-phase chromatography was used to purify the labelled hormone. The standard curves covered
the range from 1.0 to 128 pg per assay tube. Oxytocin was extracted from supernatants with an Amprep
C8 minicolumn (Code RPN 1902, Amersham, Buckinghamshire, UK), with a recovery of more than
95%. The dry residue was redissolved in 125 µL of assay buffer and 50-µL aliquots were used in
duplicate for the RIA. The sensitivity of the assay for oxytocin was 1 pg/tube. Oxytocin values are
reported in pg/mg protein. The intra- and interassay coefficients of variation proved to be 13.3% and
16.3%, respectively.
The following compounds were used; rat ghrelin (synthetized in the Department of Medical
Chemistry, University of Szeged, Szeged, Hungary), [D-Lys3]-GHRP-6 (Tocris, Bristol, UK), oxytocin
(oxytocin; Richter, Budapest, Hungary), and oxytocin antibody (Bachem, Torrance, CA, USA).
4.3. Protein Measurement
A modified Lowry method was used for the determination of total protein [20,23].
4.4. Statistical Analysis
The data are expressed as means ± S.E.M. of the results for the total number of rats
per experimental group (GraphPad Prism 4). Statistical analysis was performed by using the
Tukey–Kramer multiple comparison test. p-values less than 0.05 were considered significantly different.
Author Contributions: ti , ., . . ., a .P.; Data curation, R.S. and R.M.; Formal
analysis, R.S. and A.P., Investigation, R.S., R.M., A.H.M., Z.S., L.D., M.G., M.R., F.A.L. and A.P., Methodology,
A.H.M., L.D., G.T., J.G., M.G., D.B., A.J., C.V. and M.R., Resources, C.V., A.P., Supervision, C.V. and A.P;
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